JPMorgan Chase & Co. Increases Position in G1 Therapeutics Inc (GTHX)

JPMorgan Chase & Co. increased its stake in shares of G1 Therapeutics Inc (NASDAQ:GTHX) by 16.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 530,979 shares of the company’s stock after acquiring an additional 75,690 shares during the quarter. JPMorgan Chase & Co. owned about 1.59% of G1 Therapeutics worth $27,765,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Great West Life Assurance Co. Can increased its holdings in G1 Therapeutics by 148.3% in the 2nd quarter. Great West Life Assurance Co. Can now owns 2,612 shares of the company’s stock valued at $113,000 after buying an additional 1,560 shares during the period. Strs Ohio increased its holdings in G1 Therapeutics by 78.3% in the 2nd quarter. Strs Ohio now owns 4,100 shares of the company’s stock valued at $178,000 after buying an additional 1,800 shares during the period. WINTON GROUP Ltd bought a new stake in G1 Therapeutics in the 3rd quarter valued at $218,000. Metropolitan Life Insurance Co. NY increased its holdings in G1 Therapeutics by 48.4% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 6,818 shares of the company’s stock valued at $296,000 after buying an additional 2,224 shares during the period. Finally, State Board of Administration of Florida Retirement System bought a new stake in G1 Therapeutics in the 2nd quarter valued at $317,000. 64.04% of the stock is currently owned by institutional investors and hedge funds.

Get G1 Therapeutics alerts:

Shares of G1 Therapeutics stock opened at $38.23 on Friday. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -10.71 and a beta of 1.16. G1 Therapeutics Inc has a 52-week low of $18.03 and a 52-week high of $69.57.

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings results on Wednesday, November 7th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.08. On average, equities research analysts forecast that G1 Therapeutics Inc will post -2.49 earnings per share for the current fiscal year.

In other news, VP Jennifer K. Moses sold 750 shares of the company’s stock in a transaction dated Wednesday, September 5th. The shares were sold at an average price of $59.60, for a total value of $44,700.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Barclay A. Phillips sold 5,000 shares of the company’s stock in a transaction dated Thursday, November 15th. The stock was sold at an average price of $39.92, for a total transaction of $199,600.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 60,359 shares of company stock worth $2,958,267. 15.92% of the stock is owned by insiders.

Several equities research analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $79.00 price target on shares of G1 Therapeutics in a report on Monday, September 17th. Needham & Company LLC boosted their price target on shares of G1 Therapeutics to $76.00 and gave the company a “buy” rating in a report on Tuesday, September 18th. BidaskClub lowered shares of G1 Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 19th. BTIG Research assumed coverage on shares of G1 Therapeutics in a report on Monday, September 10th. They issued a “buy” rating and a $80.00 price target on the stock. Finally, Cowen reissued a “buy” rating on shares of G1 Therapeutics in a report on Thursday, August 9th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. G1 Therapeutics presently has an average rating of “Buy” and a consensus price target of $74.00.

TRADEMARK VIOLATION WARNING: “JPMorgan Chase & Co. Increases Position in G1 Therapeutics Inc (GTHX)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2018/12/01/jpmorgan-chase-co-increases-position-in-g1-therapeutics-inc-gthx.html.

G1 Therapeutics Profile

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.